Important Information for Your Patients Considering SLIT-Tablet Therapy for HDM-Induced Allergic Rhinitis


1. Calderón MA, Kleine-Tebbe J, Linneberg A, et al. House dust mite respiratory allergy: An overview of current therapeutic strategies. J Allergy Clin Immunol Pract. 2015;3(6):843-855.  

2. Portnoy J, Miller JD, Williams PB, et al. Environmental assessment and exposure control of dust mites: a practice parameter. Ann Allergy Asthma Immunol. 2013;111(6):465-507.

3. Calderón MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol. 2015;136(1):38-48.  

4. Bernstein DI, Bardelas JA, Fogh BS, et al. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice. Postgrad Med. 2017;129(6):590-597.

5. Han DH and Rhee C-S. Sublingual immunotherapy in allergic rhinitis. Asia Pac Allergy. 2011;1(3):123-129.

6. Cox L, Compalati E, Kundig T, et al. New directions in immunotherapy. Curr Allergy Asthma Rep. 2013;13(2):178-195.

7. Sohn MH. Efficacy and safety of subcutaneous allergen immunotherapy for allergic rhinitis. Allergy Asthma Immunol Res. 2018;10(1):1-3.   

8. Klimek L, Fox GC, Thum-oltmer S. SCIT with a high-dose house dust mite allergoid is well tolerated: safety data from pooled clinical trials and more than 10 years of daily practice analyzed in different subgroups. Allergo J Int. 2018;27(5):131-139.

9. ODACTRAÒ [Prescribing Information]. Bedminster, NJ: ALK-Abelló A/S; 2017.

10. Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015;135(6):1494-1501e6.

11. Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016;137(2):444-451.

12. ODACTRAÒ [Medication Guide]. Hørsholm, Denmark: ALK-Abelló A/S; 2017.

13. Anolik R, Schwartz AM, Sajjan S, Allen-Ramey F. Patient initiation and persistence with allergen immunotherapy. Ann Allergy Asthma Immunol. 2014;113(1):101-107.